197 related articles for article (PubMed ID: 21916910)
21. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
Sugimoto K; Uno T; Yamazaki H; Tateishi T
Br J Clin Pharmacol; 2008 Mar; 65(3):437-9. PubMed ID: 18241287
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls.
Babalola CP; Adejumo O; Ung D; Xu Z; Odetunde A; Kotila T; Falusi AG; Nagar S
J Clin Pharm Ther; 2010 Aug; 35(4):471-7. PubMed ID: 20831548
[TBL] [Abstract][Full Text] [Related]
23. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
24. Investigation of CYP2C19 allele and genotype frequencies in Iranian population using experimental and computational approaches.
Saber MM; Boroumand M; Behmanesh M
Thromb Res; 2014 Feb; 133(2):272-5. PubMed ID: 24315317
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
26. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D; Wang J; Zhang Y; Zhong D; Zhou H
Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551
[TBL] [Abstract][Full Text] [Related]
27. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population.
Ma Y; Ni W; Zhu W; Xiong Y; Deng X
Blood Press; 2011 Jun; 20(3):166-70. PubMed ID: 21332417
[TBL] [Abstract][Full Text] [Related]
28. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations.
Tassaneeyakul W; Mahatthanatrakul W; Niwatananun K; Na-Bangchang K; Tawalee A; Krikreangsak N; Cykleng U; Tassaneeyakul W
Drug Metab Pharmacokinet; 2006 Aug; 21(4):286-90. PubMed ID: 16946555
[TBL] [Abstract][Full Text] [Related]
29. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
30. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles.
Kim KA; Song WK; Kim KR; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):697-703. PubMed ID: 21054462
[TBL] [Abstract][Full Text] [Related]
31. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
32. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19 polymorphism as a predictor of personalized therapy in South Indian population.
Siddapuram SP; Banerjee R; Tandan M; Prathap N; Mitnal S; Duvvuru NR
J Assoc Physicians India; 2011 Aug; 59():490-3. PubMed ID: 21887904
[TBL] [Abstract][Full Text] [Related]
34. Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
Gu S; Sun Y; Han R; Wang L; Wang D; Wang J; Li X
BMC Med Genet; 2014 Jul; 15():83. PubMed ID: 25030528
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.
Dehbozorgi M; Kamalidehghan B; Hosseini I; Dehghanfard Z; Sangtarash MH; Firoozi M; Ahmadipour F; Meng GY; Houshmand M
Mol Med Rep; 2018 Mar; 17(3):4195-4202. PubMed ID: 29328413
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E
Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of CYP2C19 in Maharashtrian population.
Ghodke Y; Joshi K; Arya Y; Radkar A; Chiplunkar A; Shintre P; Patwardhan B
Eur J Epidemiol; 2007; 22(12):907-15. PubMed ID: 17978853
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations.
Lee SS; Lee SJ; Gwak J; Jung HJ; Thi-Le H; Song IS; Kim EY; Shin JG
Ther Drug Monit; 2007 Aug; 29(4):455-9. PubMed ID: 17667801
[TBL] [Abstract][Full Text] [Related]
39. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
40. Genetic variations and haplotypes of CYP2C19 in a Japanese population.
Fukushima-Uesaka H; Saito Y; Maekawa K; Ozawa S; Hasegawa R; Kajio H; Kuzuya N; Yasuda K; Kawamoto M; Kamatani N; Suzuki K; Yanagawa T; Tohkin M; Sawada J
Drug Metab Pharmacokinet; 2005 Aug; 20(4):300-7. PubMed ID: 16141610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
